ImunoTera

ImunoTera was founded by three researchers who developed a platform of therapeutic vaccines capable of restoring and activating the immune system to fight infectious diseases and cancer. The platform is based on a dual-function recombinant protein that can be engineered to target different types of cancer and infectious diseases. This system acts by antigen-loading and activating dendritic cells leading to the generation of target-specific cytotoxic T lymphocytes (CTL), while blocking immunosuppressive pathways. The pipeline so far includes therapeutic vaccines to control HPV-related cancer, HIV, ZIKV, and SARS-CoV-2. Our company has been pursuing therapeutic strategies targeting HPV-induced tumors such as cervical and head and neck cancers Our first product, the TERAH-7 is currently being applied in an experimental clinical showing complete regression of CIN, and HPV clearance and avoiding the need for surgery in some treated patients. In 2020, ImunoTera was one of the winners of the Innovative Women Award promoted by the Financier of Studies and Projects (Finep) related to the Brazilian Ministry of Science and Technology. In 2023, ImunoTera was Top 30 in Latin America finalists for the Bayer Foundation Women Empowerment Award. Currently, ImunoTera is part of the portfolio of companies incubated at Hospital Israelita Albert Einstein, considered the best hospital in Latin America.